Acute Lymphoblastic Leukemia
The term “non-AIDS-defining cancers” (NADCs) refers to neoplasms other than AIDS-defining malignancies that occur in individuals with HIV infection. The spectrum and incidence of various neoplasms reported among persons infected with human immunodeficiency virus (HIV) has increased, and this emerging problem has contributed to the mortality of HIV-infected persons in the current era of potent antiretroviral therapy (ART). Large, population-based studies involving registry match data have reported a wide range of cancers in association with HIV infection. Incidence of cancer among HIV-infected persons was compared with that of the general population from 1992 to 2003 in a prospective observational study conducted in the United States. However, investigators reported that the incidence of leukemia was only slightly higher in HIV-infected people (standardized incidence ratio, SIR: 2.5; 95 % CI: 1.6–3.8). Except for a higher frequency of mature B or Burkitt’s ALL in HIV-infected patients, the clinical and biologic characteristics of ALL are similar to those observed in non-immunocompromised patients. In the ART era, the treatment of ALL in HIV-positive patients should be identical to that given in non-immunosuppressed individuals.
KeywordsHuman Immunodeficiency Virus Acute Lymphoblastic Leukemia Human Immunodeficiency Virus Infection Minimal Residual Disease Standardize Incidence Ratio
Supported in part by grants from the Red Temática de Investigación Cooperativa en Cáncer (RTICC, FEDER) (RD12/0036/0029); 2014 SGR225 (GRE) Generalitat de Catalunya; PI14/01971 from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III; and Fundació Internacional Josep Carreras i Obra Social “la Caixa,” Spain.
- 8.Cancer Statistics US Working Group. United States Cancer Statistics: 1999–2010 incidence and mortality web-based report. Atlanta: Department of Health and Human Services. Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs. [Last accessed 29 December 2014].Google Scholar
- 11.Brunet S, Rabella N, Aventín A, Soler J. Acute lymphoblastic leukemia of the Burkitt’s type in a patient seropositive for the human immunodeficiency virus. Med Clin (Barc). 1987;89:527.Google Scholar
- 13.Berman M, Minowada J, Loew JM, Ramsey MM, Ebie N, Knospe WH. Burkitt cell acute lymphoblastic leukemia with partial expression of T-cell markers and subclonal chromosome abnormalities in a man with acquired immunodeficiency syndrome. Cancer Genet Cytogenet. 1985;16:341–7.CrossRefPubMedGoogle Scholar
- 19.Bacci MR, Santos JA, Zing NC, Barros DM. Acute lymphocytic leukaemia and AIDS. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-010036.
- 26.Batlle M, Ribera JM, Font A, Millà F. Burkitt-type acute lymphoblastic leukemia in a patient with human immunodeficiency virus infection. Sangre (Barc). 1991;36:249–50.Google Scholar
- 27.Pogliani EM, Rossini F, Pioltelli P, Lanzi E, Casaroli I, Bolis S, et al. A case of acute lymphoblastic leukemia in an anti-HIV positive patient. Allergol Immunopathol (Madr). 1991;19:103.Google Scholar
- 30.Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, et al. PETHEMA Group and German HIV Lymphoma Cohort. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55:2341–8.CrossRefPubMedGoogle Scholar
- 31.Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–8.CrossRefPubMedGoogle Scholar